Pricing Log in Create free account
Friday 6 November 2026 Export ROIV’s income statement to Excel — free account

Roivant Sciences Ltd.

ROIV Healthcare Biotechnology

Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.

Revenue
−33.6%
EPS
+21.2%
Free cash flow
−30.0%

Quarter to June 2026, against a year earlier

38.68 2.06 +5.63%
Market cap
$26.5B
P/E
0.0×
Fwd P/E
−27.7×
Dividend yield
—
F-score
2/9
Altman Z
28.31
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Roivant Sciences Ltd. (ROIV) revenue by segment, product and region

Annual Quarterly
Download Excel — free account

Revenue by product or service $m

Line FY2022
License, Milestone and Other Revenue 55
Product Revenue, Net 0
Revenue 55

Revenue by segment $m

Line FY2026 FY2025 FY2024
Reportable Segment 8 29 33
Revenue 8 29 33

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.